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COMPULSIVE DISORDER - A
LITERATURE REVIEW
R A Emsley, D JStein, P Oosthuizen
Similarities between schizophrenia and obsessive-compulsive
disorder (OCD) have long been recognised. Obsessive-
compulsive symptoms in patients with schizophrenia wer~jirst
described by Westphal over 100 years ago.! The disorder \,'Vas
considered to be a variant of schizophrenia. Since that time the
relationship of OCD to schizophrenia and psychosis has been
the subject of considerable debate. Unfortunately, only a few
methodologically sound studies have investigated this
relationship. Associations bet"vlTeen the two disorders have been
investigated in two ways - on the one hand the frequency of
obsessions and compulsions in patients with schizophrenia has
been assessed, and on the other hand the occurrence of
psychotic symptoms in patients with OCD has been
investigated. This article reviews the literature concerning the
co-occurrence of schizophrenia and OCD. Clinical implications
are highlighted, and avenues for further research are
suggested.
OCD IN PATIENTS WITH SCHIZOPHRENIA
Several studies have investigated the occurrence of OCD
symptoms in patients with schizophrenia, with the reported
frequency ranging from 3.5% to 25%.'-1 In a retrospective chart
review, Rosen' found prominent features of OCD in 30 (3.5%)
of 848 patients with schizophrenia. These symptoms either
preceded or coincided with the onset of the schizophrenic
symptoms. He emphasised the depressive and paranoid
features of these patients, and considered them to have a good
prognosis. In another retrospective chart review Fenton and
McGlashan' found that 21 (12.9%) of 163 DSM-III-diagnosed
schizophrenic patients had prominent OCD symptoms. Berrnan
et al." interviewed the treating physicians of 108 patients with
chronic schizophrenia and found prominent OCD symptoms in
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27 (25%). However, in a well-designed study on 77 patients
with schizophrenia or schizo-affective disorder, Eisen et ai'
found that only 6 (7.8%) also met DSM-llI-R criteria for OCD.
This prospective study employed the Structured Clinical
Interview for DSM-llI-R and the Yale-Brown Obsessive
Compulsive Scale (Y-BOCS), as well as chart review and
contact with the treating clinicians. Of the above studies, the
latter is most likely to reflect the true incidence of OCD in
patients with schizophrenia. The occurrence of OC symptoms in
patients with schzophrenia is likely to be considerably higher.
In a study limited by is small sample size, Yaryura-Tobias et ai'
reported unexpectedly high scores on the Y-BOCS and the Self-
Rated Symptom Scale for OCD in 13 patients with
schizophrenia, and found great similarities in thought process
impairment and perceptual deficits when compared with ??
OCD patients. Little is known about the clinical,
neurobiological and treatment aspects of these patients. The
need for further carefully planned prospective studies is
obvious.
QeD WITH PSYCHOTIC FEATURES
Clinical observations indicate that not all OCD patients
recognise their obsessions as being irrational or excessive. Their
ideas have usually been described as overvalued or delusional.
Kozak and Foa' have examined the matter of insight in OCD
and conclude that OCD ideas cannot be dichotomised into
those with and those without insight. They suggest that a
continuum of strength of OC beliefs is more appropriate, and
emphasise that the relationship between the degree of OC
conviction and outcome of treatment remains unclear. In 1875
du Saulle8 reported psychotic symptoms in some of the 27
OCD patients he described. The patients with psychotic
features also had poor insight and severe psychopathology.
Janet9 found psychotic symptoms in 7.7% of patients with
OCD. In a review of the literature of OCD with psychotic
features, lnsel and Akiskal10 list 9 studiesU -l9 of patients who
wereinitially diagnosed as OCD and in whom a relatively high
incidence of psychosis was found. Incidence rates for
schizophrenia in these studies range from 0.7% to 12.3%. The
authors point out that these findings should be interpreted
with caution, as these were all retrospective studies, with the
diagnoses being made by chart review. Also, standardised
criteria for diagnpsing schizophrenia were not used. Rudin12
and Muller" found that a relatively high percentage of their
patients had schizophrenia, while other studies considered
their OCD patients to be psychotic only in the presence of
paranoid thinking, or transient loss of insight. Interestingly,
many of the OCD patients with psychotic features reportedly
had a relatively good outcome.
Insel and Akiskal10emphasise that the deterioration often
seen in patients with schizophrenia is extremely rare in OCD
patients with psychotic features. The literature suggests that
psychotic features in OCD patients may often be due to a
paranoid state or a mood disorder rather than a schizophrenic
illness. More recently, Eisen and Rasmussen20 assessed 475
patients with DSM-llI-R OCD. Sixty-seven (14%) were
identified as having 'psychotic' symptoms. However, the only
psychotic symptom in 27 (6%) was lack of insight, and 14 (3%)
were actually diagnosed as schizotypal personality disorder.
The remainder of the patients met criteria for specific psychotic
disorders. Eighteen (4%) met criteri"a for schizophrenia, and
8 (2%) had a delusional disorder. OCD patients with psychotic
features were more likely to be male, single, to have received
treatment earlier, and to have had a deteriorating course. In
contrast to some earlier studies, therefore, these authors found
that OCD patients with features of schizophrenia had a poor
outcome. Clearly, there is considerable heterogeneity among
OCD patients with psychotic symptoms.
The co-occurrence of OCD and schizophrenia appears to be
greater than would be expected by chance. Taken together, the
evidence points to a small but significant subset of patients
sharing OCD and schizophrenia symptoms. Whether this
represents a distinct clinical entity, or the extremes of a
continuum, is not clear. Further prospective studies are
required to clarify this issue as well as to determine such
matters as whether these patients have other distinctive
features, whether they respond differentially to standard
treatment, and whether other treatment options - e.g.
serotonin reuptake inhibitors (SRls) combined with
antipsychotics - may be effective.Z1
SEROTONIN AND DOPAMINE
There is considerable evidence suggesting that serotonergic and
dopaminergic pathways may have particular relevance both for
patients with OCD and for those with schizophrenia. SRls are
the first-line treatment for OCD/' and dopamine-blocking
agents have been the mainstay of the treatment of
schizophrenia for many years." Furthermore, preclinical and
clinical findings have reported that dopamine plays a role in
OCD and possibly related disorders such as Tourette's
syndrome."'" Also, in treatment-resistant OCD augmentation
with haloperidol has been successful, particularly if tics are
present." The advent of the new antipsychotics has brought
renewed interest because of their combined dopaminergic and
serotonergic blocking properties. In this regard several studies,
although uncontrolled, have reported a favourable
augmentative effect with the new antipsychotic risperidone in
treatment-resistant OCD.26-JO Paradoxically, several anecdotal m
reports have arisen of OCD symptoms emerging in patients
with schizophrenia during treatment with both clozapine31'"
and risperidone."-J9The frequency of this occurrence is
unknown and it may be extremely rare, as a retrospective
review of hospital files in 142 randomly selected patients on
clozapine treatment failed to identify a single case of OCD
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symptoms worsening or emerging during treatment.'" Also, in a
prospective study of patients with schizophrenia those taking
another new antipsychotic, olanzapine, did not experience
more QC symptoms than those taking placebo."
These findings again point to a complex interrelationship
between serotonin and dopamine in the pathogenesis of QCD
and schizophrenia. It may be that the emergence of Qm
symptoms during treatmentwith the new antipsychotics is a
coincidental occurrence, or it may represent a rare idiosyncratic
reaction. Qn the other hand it may be that patients with
coexisting psychosis and QCD and patients with resistant QCD
represent two distinct subgroups with different underlying
disorders of serotonergic and doparninergic function. Patients
with QCD and psychosis may therefore experience
exacerbation of QCD symptoms with combined dopamine and
serotonin blockade, while patients with refractory QCD may
respond favourably to this intervention. The differential
response for symptoms of QCD and schizophrenia in patients
with both disorders is not entirely unexpected, as functional
brain-imaging studies have suggested an opposite pattern of
frontal lobe activity," and neuropsychological investigations
report a double dissociation of frontal lobe functioning in QCD
and schizophrenia:13 Whatever the underlying mechanisms,
increasing evidence points to the involvement of serotonergic
and dopaminergic neurotransmitter systems in patients with
coexisting QCD and schizophrenia." Future controlled trials
with drugs acting on these two systems in different ways may
shed more light on the underlyi.'g mechanisms, and may offer
better therapeutic options for these patients. The new
antipsychotics in particular may have a role to play and may
deserve exploration - not only in schizophrenia, but also in
QCD and related disorders such as Tourette's syndrome.
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